Program · weight loss treatments than facial wrinkle treatments. Weight loss is the natural step...
Transcript of Program · weight loss treatments than facial wrinkle treatments. Weight loss is the natural step...
Welcome to the
Program
The world’s first and only weight loss device that requires no surgery, endoscopy, or anesthesia*
• Placed during a brief 20-minute visit1 and passes naturally after approximately 16 weeks2*
• Patients lose an average of 10 to 15kg and 10 to 15% TBWL after approximately 16 weeks of Elipse therapy2 to 11
• 15,000 balloons distributed worldwide
• The program includes professional follow-up over 6-months along with a smart scale and app to track weight loss.**
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. **The Elipse Balloon must be used in conjunction with asupervised nutrition and behavior modification program. Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on thephysician and patient’s profile.
1. Clinical Trial Reports: DAA069 and DAA105 | 2. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241. | 3. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182. | 4. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317. | 5. Machytka E et al. Endoscopy. 2017 Feb;49(2): 154-160. | 6. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1 | 7. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22. | 8. Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA | 9. Genco et al. Submitted to SOARD. Abstract A185, presented at Obesity Week, 2018, Nashville, USA | 10. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain | 11. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States. This material is not intended for a U.S. audience. This material describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration. Our product is not available for sale in the United States.
TBWL: Total Body Weight Loss
Vast 2018 Consumer Research across Europe, Middle East, China and U.S.A.
Screening a representative panel of 9,800 patients
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
2
Patients’ demands and expectations remainunmet with existingweight loss procedures
We surveyed 9,800 overweightand obese patients around the world
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018
U.S.A U.K. Germany France
Spain Italy China U.A.E.
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
3
people are overweightor obese in the US, EU5, China and the UAE*
1 3are not fully satisfiedwith previously trieddiet plans2
78%are not fully satisfiedwith previously triedweight loss solutions1
76%
An increasing number of patients lack satisfying treatment options
2. Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q3C. On a scale of 1 to 10, where 1 isnot at all satisfied and 10 is extremely satisfied, how satisfied are you with the following? Think about your experience of the wholeprocess.Global level. Base: n=4831Satisfied: 8-10/10, neither 4-7/10, unsatisfied 1-3/10
1. Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018Q3C. On a scale of 1 to 10, where 1 is not at all satisfied and 10 is extremely satisfied, how satisfied are you with the following? Think about your experience of the whole process.Global level. Base: n=4831Satisfied: 8-10/10, neither 4-7/10, unsatisfied 1-3/10 *Based on WHO, Eurostat and US Census data
in
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
4
of those that wouldconsider HCP* intervention, would consider Elipse
60%
4.3% would consider the Elipse BalloonGlobally, 7.2% of eligible patients would considertreatment from an HCP to manage weight loss
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018, Population, Age, and Income Data takenfrom Census.gov Funnels computed using cascading base methodology Bothered by weight is determined at 4 – 7 on a 7 point scale Considerers needs to be assessed by medicalpractitioner to assess their eligibility to the treatment*HCP = Health Care Professional
Total population in consideredareas across 8 geographies
Target ages (18-65) andtarget BMI (>27)
Target household income
Bothered by their weight
Ready to act in the next 2 years
Would consider HCP intervention
Would consider Elipse
100%547.6 million
33.6%183.8 million
26.8%146.7 million
19.7%108.2 million
13.1%71.9 million
7.2%39.3 million
4.3%23.7 million
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
5
% OF OVERWEIGHT/OBESE CONSIDERING MEDICAL TREATMENT FOR THE MENTIONED FACIAL/BODY CONCERNS
Elipse is an aesthetic lifestyle treatment for moderateto high BMI patients
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q2B.Are you considering having any of the following facial or body treatments providedby a physician / healthcare professional in the next 2 years? Global level. Base: n=6394*The safety and effectiveness of the non-Elipse treatments has not been evaluated by AllurionTechnologies, Inc
more overweight and obese people considerweight loss treatments than facial wrinkle treatments
Weight loss is the natural step beforebodycontouring procedures: CoolSculpting, Liposuction, Abdominoplasty, Belkyra*
14 x42%Weight loss
6% - Hair removal
5% - Double chin
3%Facial wrinkles
3% - Excessive sweating
2% - Breast size
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
6
Aesthetics:Introducing a New Holistic Approach to the Body
SLIM
Lose weightwith Elipse
(for overweight patients)1
SCULPT
Remove stubborn fatwith Liposuctionor Cryolipolisis2
TONE
Rebuild muscle with high intensity focused
electromagnetics3
LIFT
Tighten the skin with radiofrequency4
1. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.2. Avram and Harry Lasers Surg Med. 2009 Dec;41(10):703-8.3. Jacob et al. J Drugs Dermatol. 2018 Nov 1;17(11):1229-1232.4. Moradi and Palm. J Drugs Dermatol. 2015 Sep;14(9):982-5.
The safety and effectiveness of the non-Elipse treatments has not been evaluated by Allurion Technologies, Inc
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
7
Gastric balloon procedures have a reduced uptake due to the lackof patient friendly solutions
Perceived reasons for NOT considering a weight loss balloontreatment requiring endoscopyand anesthesia
Q16. When considering the weight loss balloon treatment requiring an endoscopy and anesthesia, why are you not interested in this treatment? Global data Base: Q16 n=2377, Q18A n=4341, Q18B n=4341
49% Risk of damage to throat/oesophagus
65%49% Don’t want anesthesia38% Discomfort29% Pain15% Downtime / Recovery time
Fear of complications
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
8
3 times more patients would considerthe Elipse Balloonthan those who would considerbariatric surgery
Q4A. Have you ever discussed your weight with a health care professionalsuch as a [UK ONLY: GP/] [US ONLY: PCP] / doctor, specialist, dietician or nutritionist?Global data. Base: asked to all, n=8281
of those that wouldconsider HCP* intervention, would consider Elipse
60%
of those that would considerHCP intervention, would considerbariatric surgery
19%
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
9
more patients would preferintragastric balloons placedby swallowing versus endoscopicplacement and removal by naturalpassage versus endoscopic*
6xwould only be willing to trya treatment that doesn’t requireany surgery or anesthesia
40%
Endoscopy, anesthesia and surgeryare major barriers to treatment for overweightand obese patients
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018 Q11. Which of the following weight losstreatment options would you be willing to try if it was proven to bean effective weight loss treatment? Global data. Base: n=3687. Likely to ask HCP for solution not tried.
Q18A. What is your preference for how a weight loss balloonis placed in your stomach? Q18B. What is your preference for how a weight loss balloon at the end of your treatment is removed fromyour stomach? Global data Base: Q16 n=3028, Q18A n=6152, Q18B n=6152 Don’t know/ not sure were also included in the options to answer.*In rare cases, the Elipse Balloon may require endoscopicor surgical intervention for removal
over
×
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
10
DriversNon-surgical treatment is a key preference factor for those considering weight loss treatment
IMPORTANT FACTORS IN HCP INTERVENTION TREATMENTTop 6 most important
Q10. What would you be looking for from a physician/health care provider administered weight loss treatment?Global data. Base: n=2461. Likely to ask HCP for solution not tried.
Non surgical treatment
No anesthesia is required
Recommended bymy doctor/provider
Quick results
Provides results I can see
Gives me the results I want 20%
21%
21%
24%
25%
28%
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
11
The Elipse Balloon is the world’sfirst and only weight loss devicerequiring no surgery, endoscopy, or anesthesia*
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
Balloon film• Much thinner than silicone balloons1
• Flexible enough to fold intoa capsule and safely pass throughthe GI tract2,3,4
• Durable enough to spend monthsin the stomach2,3,4
01
1. Internal Allurion lab notebook data2. Clinical Reports: DAA018, DAA069 and DAA1053. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.4. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
12
1. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
Swallowing• The balloon is rolled into the
capsule and swallowed along witha thin Delivery Catheter to facilitate filling
• In a recent clinical study1 99.9% of patients (n 1623) were able to swallow the device with only 32%needing stylet assistance
02
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
The Elipse Balloon is the world’sfirst and only weight loss devicerequiring no surgery, endoscopy, or anesthesia*
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
13
Fill valve• Made from thin film
• Seals shut after the Delivery Catheter is pulled out
03
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
The Elipse Balloon is the world’sfirst and only weight loss devicerequiring no surgery, endoscopy, or anesthesia*
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
14
1. Clinical Reports: DAA018, DAA069 and DAA1052. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.3. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.
04Release valve• Made from a thin film
and a degradable filament
• Only exposed to the insideof the device to allow for controlled opening1
• Weakens over time, then opens at pre-determined time allowingthe balloon to empty1,2,3
The Elipse Balloon is the world’sfirst and only weight loss devicerequiring no surgery, endoscopy, or anesthesia*
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
15
1. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
The Elipse Balloon is swallowed in a physician’s office
01
An improved patient experiencefrom start to finish
The Elipse Balloon is filled with 550ml of liquid in the stomach
02At approximately 16 weeks after placement, the Elipse Balloon self-empties and passes naturally1*
03
Two X-rays of the patient will confirm1) that the capsule is
in the right position2) a second X-ray to confirm
the balloon is filled.
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
16
Patients want to get resultsand achieve lifestyle changeswithout surgery, endoscopy or anesthesia
IMPORTANT FACTORS FOR HCP TREATMENT ACCORDING TO MARKET RESEARCH
Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018Q10. What would you be looking for from a physician/ health care provider administered weight loss treatment? Global data. Base: n=2461Q19A. What do you like about the Elipse Balloon? Global data. Base: n=2538
01A simple procedure
Long term lifestyle changes
Makes me feel good about myself
Gives me the results I want
Provides results I can see
Quick results
Recommended by my doctor/provider
No surgery or anesthesia is required
Non surgical treatment 28%
25%
24%
21%
21%
20%
20%
20%
02Effective results
03Multidisciplinary support
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
17
*In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal
2. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.3. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.4. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.5. Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.6. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-17. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.8. Ienca et al. Submitted to SOARD. Abstract A278, presentedat Obesity Week, 2018, Nashville, USA9. Genco et al. Submitted to SOARD. Abstract A185, presentedat Obesity Week, 2018, Nashville, USA10. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain11. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States.
**The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program. Allurionadvises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
TBWL: Total Body Weight Loss
The Elipse Balloon is swallowedduring a brief 20 minute visit1 and passes naturally afterapproximately 16 weeks2*
Your patient enjoys the privacyof an outpatient treatment: no one in his or her circle needsto know they had the placement
01A swift experience
The first and only game-changingdevice that matches patients’ needsand expectations
After approximately 16 weeksof Elipse therapy, patients losean average of 10 to 15kgand 10 to 15% TBWL2 to 11.
Patients receive medical and nutritional support for the entire duration of the program along with a smartphone app and a connected scale**
02Effective results
03Multidisciplinary support
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
18
Efficacy and safety of the Elipse Balloonhas been demonstrated in multiple clinical studies
1. Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.2. Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.3. Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-14. Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.5. Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.
YearPublished
n MeanStartingBMI (kg/m2)
WeightLoss
EU Multi-Center Study1
2017 34 34.8(27.0-40.0)
10% TBL3.9 ↓BMI
Greek Experience2
2017 12 36.1 14.6% TBL5.4 ↓BMI15.4kg/34lbs
ItalianExperience3
2017 38 38.6 11.6% TBL4.2 ↓BMI12.7kg/28lbs
Faisal ClinicExperience4
2017 51 32.1(27.3-39.7)
10.4% TBL40.8%EWL3.4 ↓BMI
Kuwait MulticenterStudy5
2017 135 32.1(27.3-39.7)
15.1% TBL4.9 ↓BMI13kg/28.6lbs
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
19
1. Ienca et al. Submitted to SOARD. Abstract A278,presented at Obesity Week, 2018, Nashville, USA2. Genco et al. Submitted to SOARD. Abstract A185,presented at Obesity Week, 2018, Nashville, USA3. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-12414. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain5. Raftopoulos et al. Abstract 1978. Presented at ACS 2019,San Francisco, United States.
Efficacy and safety of the Elipse Balloonhas been demonstrated in multiple clinical studies
YearPublished
n Mean StartingBMI (kg/m2)
WeightLoss
Expanding the Reach of Intragastric Balloons: First Multicenter Results of ElipseBalloon in Non-Core User Groups1
2019(Submittedfor publication)
64 35±4.6 After 4 months, at the time of excretion16 %TBL5.7↓ BMI
Italy Metabolic Multicenter Study2 2019(Submittedfor publication)
324 36.8(27-45)
13.75% TBL4.98 ↓BMI14.3 Kg
Kuwait 1 Year Post-ExcretionFollow-up3
2019 112 34.3 10.9% TBL at 6 months7.9% TBL at 1 yearpost device excretion
Multi-Center Experience in 1623Consecutive Patients4
2019(Submittedfor publication)
1623 34.2±5.4 After 4 months,13.6±5.7% TBL4.9↓ BMI99.9% of patients were able to swallow the device
An Intensive 16-week Nutritional, Exercise and Behavior Modification Program: Comparison Withor Without the Elipse IntragastricBalloon5
2019 471 Elipse plus LI36.7+5.7LI alone36.8+5.0LI = lifestyle intervention
After 4 months,14.1+5.2 (Elipse + LI) vs.6.7+4.6 (LI Alone) %TBWL
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
20
of patients were able to swallow the device
99.9%All metabolic parametersimproved (measured in a subset of 406 patients)
TBWL was13.6±5.7%
Mean Weight Loss12.9±6.5 kg
BMI reduction4.9±3.3 kg/m2
4
Excellent safety profile withproven efficacyLargest Elipse Data Collection to Date1
1623 consecutive patients, in 19 centers, across 7 countries
1. Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain
months
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
21
Intensive lifestylemodification includeda structuredcurriculum-basednutritional, exerciseand behaviormodification program
Lifestyle modificationWhen coupled with a 16-week intensive lifestylemodification, Elipse leads to significant weight lossvs. lifestyle modification alone1*.
1. Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States.*The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification program.Allurion advises a 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
0
10
20
30
40
50
60
70
80
% of patients achieving 10% TBWL
PERCENTAGE OF PATIENTS ACHIEVING 10% TBWL AT 16 WEEKS
Elipse + Lifestyle Intervention (n=58)
Lifestyle Intervention Alone(n=413)
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
22
of average weight loss was sustained at
12
A temporary balloon does not mean temporary weight loss
1. Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.
monthfollow up
Lose Weight and Keep It Off
72% One clinical study with 95 patients has shown that 72% of average weight loss with Elipse can be sustained at 12 month follow up.
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
0 1 2 3 4 5 6
wei
ghtl
oss
(kg)
months after IGB Placement
Peter at. al., 2010
Totte at al., 2011
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
23
Weight Loss withGastric Balloons
1. Gaur S, et al. Gastrointestinal endoscopy, 2015 81: 1330-1336
WEIGHT LOSS CURVE AFTER ORBERA IGB PLACEMENT1
of weight loss of a 6-month Orbera balloonoccurs in the first threemonths1
80%Please note these are results from Orbera Gastric Balloon
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
24
Elipse Safety ProfileAllurion Internal Vigilance Data
≈ 98%No reportedadverse events
In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. Some individuals may not be eligible to receive the Elipse Balloon. Doctors take a detailed medical history and perform a physical examination to determine patients’ eligibility.
The Elipse Balloon is a temporary weight loss aid for adults over the age of 18 who are overweight or obese, defined as a body mass index (BMI) ≥ 27. The Elipse Balloon can only be administered by a healthcare professional who is knowledgeable about the use of the Elipse Balloon.
The Elipse Balloon must be used in conjunction with a supervisednutrition and behavior modification program. Allurion advisesa 6-month follow-up program. Its duration is defined by the physician, and may vary depending on the physician and patient’s profile.
ADVERSE EVENTS RATES (%)MARCH 2016 – JUNE 2019
Total units distributed= 15,200
Total adverse events reported were lessthan 2% of total Elipse Balloons placed
The 10 Most Relevant TypesPremature Deflation 0.43%Intolerance 0.25%Small Bowel Obstruction 0.11% Hyperinflation 0.05%Dysphagia 0.05%Gastric Outlet Obstruction 0.03%Gastric Perforation 0.02%Incomplete Device Emptying 0.02%Pancreatitis 0.01%Gastroparesis 0.01%
In rare cases, the empty balloonmay be vomited instead of passing through the GI tract. Althoughstartling to the patient, vomitingof the balloon has not been associated with any reportedadverse events to date.
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
25
• Early removal: 7.5%• Serious side effects
are not common
Common side effects are pain, nausea and GERD
1. Abu Dayyeh BK. Gastrointestinal Endoscopy. 2015;82(3):425-438
Side Effect Rate %
Pain 33.7
Nausea 29
GERD 18.5
Gastric erosions/ulcers 12/2
Migration 1.4
Small bowel obstruction 0.3
Perforation 0.1
Death 0.08
META-ANALYSIS OF 80 ORBERA IGB STUDIES INCLUDING 8,506 PATIENTS1
Please note that this is the safety profile of Orbera Gastric Balloon
Weight loss with Elipse therapymay improve patient comorbidities1,2
Diastolic Blood Pressure(↓5-5.8 mmHg)
04Systolic Blood Pressure(↓7-9.6 mmHg)
03Triglycerides(↓16.4-34 mg/dl)
02WaistCircumference, (↓8.4-12.5 cm)
01
1. Machytka et al Endoscopy. 2017 Feb;49(2):154-160.2. Genco, A., et al. Obesity Surgery, 2017, 28(2), 405-409
Treatment produced a reduction in the factorsrelated to clinical diagnosis of metabolic syndrome such as
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
26
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
27
Elipse therapy may improvepatient quality of life1
CHANGE IN IWQOL SCORE FROM BASELINE TO TRIAL EXIT
1. Machytka et al Endoscopy. 2017 Feb;49(2):154-160.*A small percentage of patients don’t respond to the treatment.
Elipse therapyimproved the meanQOL acrossall domains*
0%
20%
40%
60%
80%
100%
Overall Physical function Self-esteem Sexual life Public distress Work
+12,2 +12,9
+18,8
+7,7
Baseline (n=27)
Trial exit (n=26)
+7,7 +8,2
Highly attractive practice economics.Business case for 3 levelsof account productivity.
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
28
*Gross profit per treatment divided by physician time spent per treatment: consultation: 1x30 min, placement: 20 min, follow-up: 1x10 min
$5000program price
Price of the balloon $1 722
Dietician fees $400
Psychologist/coach fees $115
Out of pocket expenses (XRAY) $200
HCP fees $2563
Monthly productivity 5 balloons 10 balloons 17 balloons
Monthly practice revenue $25 k $50 k $85 k
Monthly gross profit $13 k $26 k $44 k
Annual practice revenue $300 k $600 k $1,020 k
Annual gross profit $154 k $308 k $523 kTime allocation (days a month) > 1 day/m > 2 days/m > 3 days/m
PHYSICIAN GROSS PROFIT
Time spent by treatment 60 min
Physician gross profit per hour* $2563/h
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
29
Get support from day 1• Place your first 10 balloons
with the support of the Allurion team
• Leverage in-clinicmarketing tools
• Get support in creatingyour multidisciplinaryElipse Program
Benefit from Allurionexpertise• Clinical expertise
• Market research
• Allurion Academy
• Staff training
• Online advertising
• Marketing rewards
• Customer Care Manager
Increase patient engagement and follow-up quality• Long-term program
• Connected smart scale
• Allurion app
Dedicated support to develop Elipse activities
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
30
Testimonials
“Before, I was so big that I had a lot of difficulties with mobilityand there were days when I wouldn't be able to leave the house. Now, I feel like I have my life back again.”
Michael, 67, UK, in the Daily Mail
“I swallowed the capsule without too much difficulty —I felt a bit queasy but nothing more (…) I’ve lost 25 inches all over and I can fit into a size 16 comfortably.”
Kayleigh, 28, UK, in the Daily Mail – Spire Thames Valley Dr Humadi
“It was fantastic (...) I’ve lost 16 pounds in 4 weeks, my energy and my confidence are back, I’m fitting into clothesI haven’t worn for 30 years!”
Hetsie, 42, UK, on Channel 4
“I was going straight to obesity (…) I finished the treatment6 months ago but I still feel full faster than before. (…) I lost 20 kilos thanks to the Elipse Balloon.”
Véronique, 50, France, in Femme Actuelle
Actual Elipse Patient*Results may vary from one participant to another. A small percentage of patients don’t respond to the treatment.
Inspire others: share your patient success stories
Our purpose
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
31
To help people achievetheir full potential withinnovative, scalable, and trusted experiences
Veronique, 50Lost 20kg
No longer afraid to bein family photos
Claire, 42Lost 10kg
Can run after her son without losing her breath
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
32
Our purposeA message fromour founders
Ethics first01Opennessand transparency02Scientific validation03Data-drivendecision making04EmployeeFulfillment05
©20
19AL
LUR
ION
TEC
HN
OLO
GIE
S -P
RIO
PRIE
TAR
Y IN
FOR
MAT
ION
–C
ON
FID
ENTI
AL
33
2009Allurion is founded by twoHarvard Medical Schoolstudents, supported by a world class scientific advisory board
2017Allurion raises an additional26.5 million USD
2019Commercial in 21 countries in Europe, the Middle East and S. America
15,000 balloons distributedworldwide
100% growth per year:join the Allurion success story
EUROPE MIDDLE-EAST LATIN AMERICA
PT ES
FR
DE
IT
GR
UK
EG
SA
IQ
CHL
KW
BHR
QAUAE
OM
NL
BE